POS0684 OMNIPRESENT POOR PROGNOSTIC FACTORS IN EARLY RHEUMATOID ARTHRITIS IN THE IMPROVED COHORT; IS EARLIER BDMARD TREATMENT ESCALATION NECESSARY FOR EVERYONE?
Authors: S. A. Bergstra, J. Van der Pol, T. Huizinga, M. Steup-Beekman, M. De Witt, C. F. Allaart
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> The EULAR recommendations for the treatment of RA state, by expert opinion, that if a treatment target is not achieved with the first csDMARD strategy, addition of a bDMARD or a tsDMARD should be considered if at least 1 poor prognostic factor (PPF) is present. PPFs are defined as: moderate to high disease activity after csDMARDs, high acute phase reactant levels, high swollen joint counts, presence of RF and/or ACPA (especially in high levels), combinations of aforementioned PPFs and presence of early erosions. <h3>Objectives:</h3> To investigate the presence of PPFs in early RA patients, aiming to compare the clinical response on either csDMARD combination or bDMARD therapy in relation to presence or absence of PPFs, in the IMPROVED cohort. <h3>Methods:</h3> In the IMPROVED study, 479 patients with RA (2010-criteria) started treatment with MTX and a 4-month tapered high dose of prednisone bridging scheme. Patients not in early remission (DAS ≥1.6) after 4 months of the initial treatment were randomized to either 4 months MTX + HCQ + SSZ + continued low dose prednisone (arm 1) or to 4 months MTX + adalimumab (arm 2). A maximum of 5 PPFs could be present in any patient. High acute phase reactants were defined as CRP ≥0.8 mg/dl or ESR levels &gt;20 mm/hour in women and &gt;15 mm/hour in men. For swollen joint count (SJC), we defined a high SJC as &gt;10 in our main analysis and performed a sensitivity analysis with a definition of high SJC when the SJC was &gt;4. <h3>Results:</h3> Almost all RA patients had at least one PPF as mentioned in the EULAR recommendations. Presence of each PPF is displayed in Figure 1. High inflammatory parameters and presence of antibodies at baseline were the most frequent PPFs (present in 366 and 390 patients, respectively). Presence of PPFs was evenly distributed between the randomization arms (Figure 1b). Only 5 patients (1%) had no PPFs in the main analysis and only 10 (2%) in the sensitivity analysis. Of these, 2/5 and 2/10 patients did not achieve early remission and were randomized to the two treatment arms. Due to these small numbers, no further comparison in treatment response was done. In total, 65 patients with PPFs were evenly randomized to each study arm. Mean (SD) DAS change in arm 1 was -0.47 (-0.79) and in arm 2 -0.57 (-0.74), p=0.48. Changes in HAQ were similar, median (IQR) HAQ change was -0.13 (-0.13; 0.13) in arm 1 and -0.13 (-0.25; 0.25) in arm 2, p=0.13. In the 5 and 6 patients that showed progression of radiographic damage at year 1, median (IQR) progression was 1 (0.5; 2) in arm 1 and 0.5 (0.5; 1) in arm 2, p=0.48. <h3>Conclusion:</h3> Empirically identified PPFs were present in up to 99% of patients with early RA. High prevalence of PPFs is probably due to a large overlap between these PPFs and the 2010 RA classification criteria. According to current EULAR recommendations, it is recommended to start a b/tsDMARD in patients with PPF after failing first therapy with MTX and GC bridging. After failure to achieve the treatment target on this first treatment, we found no significantly better response in these patients on bDMARDs compared to csDMARDs. No comparison could be made with non-PPF patients. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Sytske Anne Bergstra Speaker fee from Benecke, ASPIRE grant from Pfizer, Joy van der Pol: None declared, Tom Huizinga: None declared, Margreet Steup-Beekman: None declared, Marianne De Witt: None declared, Cornelia F. Allaart The study was designed by the investigators and financially supported by Abbott. Data collection, trial management, data collection, data analysis and preparation of the manuscript were performed by the authors.